Navigation Links
Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
Date:9/22/2008

n or more than 60 years of age). The prognostic value of various molecular markers will also be studied.

The trial is expected to start this fall and will be conducted at various sites in France.

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Laromustine (Cloretazine(R) (VNP40101M)), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia (AML). The Company is also conducting clinical trials of laromustine (Cloretazine(R) (VNP40101M)) with cytarabine in elderly patients with AML, with temozolomide in patients with brain tumors, and with stem cell transplants in patients with advanced hematologic malignancies. A Phase III trial of laromustine (Cloretazine(R) (VNP40101M)) in combination with standard induction therapy in previously untreated AML and high-risk myelodysplastic syndrome (MDS) patients is expected to start this fall. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's web site at http://www.vionpharm.com.

About Institut Paoli-Calmettes

The Institut Paoli-Calmettes Cancer Center (IPC) is a private non-profit institution. Located in Marseille, IPC is a regional university hospital that is part of a network of 20 cancer treatment centers in France. Institut Paoli-Calmettes sets out to organize and prioritize the synergies between fundamental research, transfer laboratories, biotechnology companies and hospital departments. Employing the latest in innovation, Institut Paol
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... According to a new ... Devices Market (Embolic Protection, Chronic Total Occlusion, Atherectomy, ... Filters, Stents, Balloons and Accessories) - Forecasts to ... Peripheral Vascular Devices Market is expected to reach ... of 7.4% from 2014 to 2019. ...
(Date:6/3/2015)...  SurgiQuest®, Inc. ("SurgiQuest", the "Company"), a leading ... surgery (MIS) announced today that surgeons have successfully ... Adoption has risen rapidly with a 150% growth ... the company,s expansion from robotics into the general ... over 45 countries.   The AirSeal ...
(Date:6/3/2015)... , June 3, 2015 PillPack, the pharmacy ... a $50 million round of financing led by CRV ... and Sherpa Ventures. The capital will be used to ... and build retail pharmacies in US markets. ... a better, simpler pharmacy experience that folks absolutely love," ...
Breaking Medicine Technology:The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 2The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 3The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 4Rapid Procedure Growth With SurgiQuest's AirSeal System 2PillPack Raises $50 Million to Build Retail Footprint and Accelerate Growth 2PillPack Raises $50 Million to Build Retail Footprint and Accelerate Growth 3
... , MELBOURNE, Australia, Nov. 18 ... pleased to announce a successful capital raising of A$15.6 ... investors, taking the company,s cash reserves to approximately A$24 ... Orbis, an existing Starpharma shareholder and a highly regarded ...
... Nov. 18 Rules-Based Medicine, Inc. (RBM) today announced it ... Covance Inc. (NYSE: CVD ) that will provide ... technologies and services for use in drug development. Under terms ... third-party provider of multiplexed protein biomarker testing services, and RBM ...
Cached Medicine Technology:Starpharma Announces $15.6 million Capital Raising 2Starpharma Announces $15.6 million Capital Raising 3Rules-Based Medicine Forms Biomarker Alliance With Covance Inc. 2Rules-Based Medicine Forms Biomarker Alliance With Covance Inc. 3
(Date:6/3/2015)... (PRWEB) June 03, 2015 Researchers at ... biomarkers for mesothelioma and say the tried-and-true marker mesothelin ... posted an article on the research. Click here ... University’s National Center for Asbestos Related Diseases say, even ... results, it is still preferable to fibulin-3 for identifying ...
(Date:6/3/2015)... Pittsburgh, PA (PRWEB) June 03, 2015 ... basis can cause discomfort in the back, neck, shoulders ... or other musculoskeletal injuries. In addition, recent research links ... a number of chronic diseases. Fortunately, three inventors from ... than sit at a desk. , They have developed ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 On Sunday, ... the world will gather in their local communities to ... of cities across the U.S. and abroad will hold ... bring attention to the ongoing challenges of cancer survivorship, ... cancer diagnosis can be fruitful, rewarding, and inspiring.,  , ...
(Date:6/3/2015)... 03, 2015 Fourroux Prosthetics, located at ... will celebrate its grand opening with a ribbon cutting ... prosthetic center of its kind in the area, Fourroux ... care and outcomes through use of patented advanced prosthetics ... CEO of Fourroux Prosthetics, states, “Our goal has always ...
(Date:6/3/2015)... are challenging and unpredictable times for traditional organizations across ... are rewriting the rules for business as we knew ... businesses to take on a more agile approach in ... On top of this there is a growing trend ... new innovation and approaches to business. , The manager ...
Breaking Medicine News(10 mins):Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2Health News:Adjustable Height Tabletop Unit Invented by Three InventHelp® Clients (TOR-9278) 2Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 2Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 3Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 4Health News:Fourroux Prosthetics Atlanta to Have Grand Opening Gala & Ribbon Cutting Ceremony 2Health News:Chief Digital Officer of Travelex joins Bayer, Abellio and Just Eat at The Open Mobile Summit London 2
... to turn back the clock on aging stem cells ... in a fracture every three seconds worldwide, according to ... the right signals could help aging stem cells act ... death and disability associated with a frail framework, Georgia ...
... WEDNESDAY, June 8 (HealthDay News) -- The U.S. Food and ... the popular statin Zocor because of an increased risk of ... This risk has been seen among some people taking 80 ... year of treatment, the agency said. In light of this, ...
... winter 2009-2010 was much more widespread than was previously realised, research ... year at the end of the H1N1 flu season showed that ... of the 44 per cent who tested positive had contracted swine ... flu, or had been vaccinated. The research, led by ...
... Randy Dotinga HealthDay Reporter , WEDNESDAY, June 8 (HealthDay ... may be available in the United States as soon as this ... for the scans to be of much help for those ... earlier diagnosis, which can be important to people who want to ...
... HealthDay Reporter , WEDNESDAY, June 8 (HealthDay News) -- Girls ... explain some cases of autism in families with no history ... a certain number of duplications or deletions of one or ... explained Dr. Christian Schaaf, an assistant professor in the department ...
... The University of Alabama at Birmingham has taken a ... patient care with its acquisition of the first cell-processing workstation ... States. Richard Marchase, Ph.D., vice president for Research ... history of breaking ground in the cell-therapy arena. We are ...
Cached Medicine News:Health News:Researchers work to turn back the clock on bone-producing stem cells 2Health News:Researchers work to turn back the clock on bone-producing stem cells 3Health News:Researchers work to turn back the clock on bone-producing stem cells 4Health News:FDA Places New Warning Label on Zocor 2Health News:FDA Places New Warning Label on Zocor 3Health News:Brain Scans to Spot Alzheimer's May Be Available This Year 2Health News:Girls May Be More Resistant to Autism Than Boys: Study 2Health News:Girls May Be More Resistant to Autism Than Boys: Study 3Health News:Girls May Be More Resistant to Autism Than Boys: Study 4Health News:UAB first in US with cell-processing workstation 2Health News:UAB first in US with cell-processing workstation 3
Reciprocating shaker specifically for platelet bags....
... quantitative determination of progesterone ... Progesterone EIA is ... of competitive binding between ... specimen and progesterone-HRP conjugate ...
... With the introduction of the innovative GenePaint ... a genome-wide scale is much easier. The ... tightly temperature-controlled manner all steps required for ... microscope slide formats. This includes fixing, staining, ...
... Labcold platelet incubators provide accurate and ... have incorporated all of the same ... are found in the Labcold BS ... levels of product security. An independent ...
Medicine Products: